Fact CheckerSign in

NCT06802861Recruiting

Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia

Source: ClinicalTrials.gov · Last updated 10 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This study's primary purpose is to determine the relationship between aspirin metabolism and markers of metabolic dysfunction among patients at risk for preeclampsia.

Status (registry)
Recruiting
Study type
Observational
Enrollment
50 (estimated)
First submitted
24 Jan 2025
Start date
1 Jan 2025
Primary completion date
31 Jul 2026
Lead sponsor
University of Tennessee Graduate School of Medicine
Diseases
Obesity
NCT number
NCT06802861

What you commit to

  • Study type: Observational
  • Planned participants: 50
  • From 1 Jan 2025 to the primary completion date, 31 Jul 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Lab values

  • Type 2 Diabetes Mellitus
    • Type 1 Diabetes Mellitus
    • Current gestational diabetes mellitus
    • Current/active platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura/ITP, thrombotic thrombocytopenic purpura/TTP, von Willebrand disease, etc.)
    • Thrombophilia
    • Current use of NSAID for other indication (indomethacin, ibuprofen, etc.)
    • Current use of other immune-modulating agents and biologics (hydroxychloroquine, azathioprine, 6-mercaptopurine, IL-6 inhibitors, etc.)
    • Current or recent use of steroids
    • Current use of prophylactic or therapeutic anticoagulation
    • Medical contraindication to aspirin therapy
    • Molar pregnancy
    • Renal disease
    • Inability or unwillingness to give informed consent
    • Current psychiatric illness/social situation that would limit compliance with study requirements, as determined by the principal investigators

Who the study is looking for

  • Recommended aspirin for pre-eclampsia prevention by OB/GYN or MFM specialist based on ACOG and USPSTF guidelines (1 high risk factor, 2+ moderate risk factors)
    • Willingness to adhere to aspirin therapy
    • Willingness to undergo 2h OGTT for serum and urine collection in addition to survey collection, indirect calorimetry, body composition measures, neonatal measures, etc.
    • Gestational age at enrollment \<16 weeks
    • Ability to speak, read, and communicate via English

Age in the registry: 18 years to 45 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Tennessee Medical Center
Coordinator of this site? Confirm its status		KnoxvilleUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.